Aripiprazole for Schizophrenia Outpatients Completing BMS Clinical Trials
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide aripiprazole to schizophrenic outpatients and
Community Treated Patients who are currently receiving aripiprazole therapy on another BMS
sponsored clinical trial.
Phase:
Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.